https://www.selleckchem.com/pr....oducts/aprotinin.htm
This broad group spanned the full range of the functional score progression observed in Study 16. Conclusions This analysis, applying predictions derived using an ML model to a novel methodology for subgroup identification, ascertained a statistically significant edaravone treatment effect in a cohort of participants with broader disease characteristics than the Study 19 inclusion criteria. This novel methodology may assist clinical interpretation of study results and potentially inform efficient future clinical trial design strategie
Like
Comment
Share
